Not Yet RecruitingNot Applicable

ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes)

United States80 participantsStarted 2026-10-08

Plain-language summary

To help people with high-risk cancer variants to follow cancer surveillance guidelines and lower their risk of developing the disease.

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Female participants.
✓. 18 years of age or older;
✓. With known deleterious/pathogenic mutation or likely pathogenic/deleterious variant in HBOC genes (BRCA1/2) or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, EPCAM);
✓. Speaks and reads English or Spanish; and
✓. Has access to a smartphone with operating system compatible with iOS/Android applications.
✓. Female participants.
✓. With known deleterious/pathogenic mutation or likely pathogenic/deleterious variant in HBOC genes (BRCA1/2) or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, EPCAM);
✓. Age criteria met by pathogenic variants as listed below:

✕. Unwilling or unable to provide consent; or
✕. Does not have access to a smartphone or is unable to access the application on their phone;
✕. Unwilling or unable to provide consent;
✕. No deleterious or pathogenic variant in HBOC genes (BRCA1/2), or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, or EPCAM);
✕. Does not have access to a smartphone or is unable to access the application on their phone.
✕. Actively being treated for malignancy with cytotoxic therapy.
✕. History of gynecologic or breast malignancy; or
✕. Has previously undergone bilateral salpingo-oophorectomy (for BRCA1/2).

Safety and adverse events (AEs).

Timeframe: Through study completion; an average of 1 year

NCT IDNCT07565467

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2031-03-01

Jose Rauh-Hain, MD

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Female participants.
✓. 18 years of age or older;
✓. With known deleterious/pathogenic mutation or likely pathogenic/deleterious variant in HBOC genes (BRCA1/2) or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, EPCAM);
✓. Speaks and reads English or Spanish; and
✓. Has access to a smartphone with operating system compatible with iOS/Android applications.
✓. Female participants.
✓. With known deleterious/pathogenic mutation or likely pathogenic/deleterious variant in HBOC genes (BRCA1/2) or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, EPCAM);
✓. Age criteria met by pathogenic variants as listed below:

✕. Unwilling or unable to provide consent; or
✕. Does not have access to a smartphone or is unable to access the application on their phone;
✕. Unwilling or unable to provide consent;
✕. No deleterious or pathogenic variant in HBOC genes (BRCA1/2), or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, or EPCAM);
✕. Does not have access to a smartphone or is unable to access the application on their phone.
✕. Actively being treated for malignancy with cytotoxic therapy.
✕. History of gynecologic or breast malignancy; or
✕. Has previously undergone bilateral salpingo-oophorectomy (for BRCA1/2).